

WEST Search History

Updated
9/30/02
108

DATE: Monday, September 30, 2002

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=AND

| | | | |
|----|--|-------|----|
| L1 | (immunother\$ or passive\$).clm. | 10093 | L1 |
| L2 | L1 and coli.clm. | 16 | L2 |
| L3 | L1 and yersinia.clm. | 1 | L3 |
| L4 | L1 and citrobacter.clm. | 3 | L4 |
| L5 | L1 and hafnia.clm. | 16 | L5 |
| L6 | L5 or l4 or l3 or l2 | 35 | L6 |
| L7 | (intimin or invasin or intimin\$ or invasin\$).ti,ab,clm. | 18 | L7 |

END OF SEARCH HISTORY

WEST

Generate Collection

Print

L7: Entry 7 of 18

File: USPT

Jun 12, 2001

DOCUMENT-IDENTIFIER: US 6245892 B1

TITLE: Invaplex from gram negative bacteria, method of purification and methods of use

Abstract Text (1):

Invaplex, a novel composition comprising invasin proteins and LPS from gram-negative bacteria is described as well as methods of using the novel composition as an adjuvant and a diagnostic tool.

CLAIMS:

1. An immunogenic composition comprising an isolated lipopolysaccharide-protein complex (Invaplex) isolated from a water extract of gram-negative bacteria, wherein the complex is composed of at least one invasin protein associated with LPS of said gram-negative bacteria.
7. A composition according to claim 4 wherein said Invaplex comprises at least one invasin protein selected from the group consisting of IpaA, IpaB, IpaC, IpaD and LPS.
9. A composition according to claim 8 wherein said Invaplex comprises at least one invasin protein selected from the group consisting of IpaA, IpaB, IpaC, IpaD and LPS.
17. A method for detecting gram-negative bacterial infection in a biological sample comprising
 - (i) contacting a sample with a solid surface to which is attached an Invaplex isolated from bacteria suspected of causing the bacterial infection; and
 - (ii) detecting the presence or absence of a complex formed between said isolated Invaplex and antibodies specific therefor in said sample wherein the presence of said complex indicates the presence of said bacterial infection, wherein the isolated Invaplex is an immunogenic lipopolysaccharide-protein complex that has been isolated from a water extract of the gram-negative bacteria, is an adjuvant and is composed of at least one invasin protein associated with LPS of the gram-negative bacteria.
19. A method to elicit an antigen-specific immune response in a subject, said method comprising administering to said subject an Invaplex isolated from a gram-negative bacteria along with said antigen wherein said antigen-specific immune response is chosen from the group consisting of cell-mediated immune response, humoral immune response, and mucosal immune response, wherein the isolated Invaplex is an immunogenic lipopolysaccharide-protein complex that is isolated from a water extract of gram-negative bacteria, is an adjuvant and is composed of at least one invasin protein associated with LPS of said gram-negative bacteria.

WEST

Generate Collection

Print

L7: Entry 5 of 18

File: USPT

Aug 21, 2001

DOCUMENT-IDENTIFIER: US 6277379 B1

TITLE: Use of purified invaplex from gram negative bacteria as a vaccine

CLAIMS:

1. A vaccine for providing immune protection against infection with gram negative bacteria, said vaccine comprising an isolated lipopolysaccharide-protein complex isolated from a water extract of said gram-negative bacteria in an amount effective to elicit protective antibodies in a subject to said gram-negative bacteria and a pharmaceutically acceptable carrier, wherein the complex is in its native conformation and composed of at least one invasin protein associated with LPS of said gram-negative bacteria.
4. A pharmaceutical composition comprising at least one isolated lipopolysaccharide-invasin protein complex in its native conformation isolated from a water extract of a gram-negative bacteria and a pharmaceutically acceptable excipient.
6. The vaccine according to claim 1, comprising a dose containing 1 ng. to 10 mg. of said isolated lipopolysaccharide-invasin protein complex.
7. The vaccine of claim 1, comprising a dose containing from 100 ng. to 500 ug of said isolated lipopolysaccharide-invasin protein complex.
9. A method comprising administering to a subject a vaccine comprising a pharmaceutically acceptable excipient and an effective immunizing amount of isolated lipopolysaccharide-invasin protein complex isolated from a water extract in its native conformation, for prophylactic or therapeutic use in generating an immune response in a subject with a gram-negative bacterial infection.

WEST

Generate Collection

Print

L7: Entry 14 of 18

File: USPT

May 5, 1998

DOCUMENT-IDENTIFIER: US 5747293 A

TITLE: Intimin-like proteins of E. coliAbstract Text (1):

The invention is related to antibodies, particularly monoclonal antibodies, which recognize particularly epitopes of the intimin protein of enteropathogenic E. coli and enterohemorrhagic E. coli, methods of detecting such E. coli by use of these antibodies, and kits containing these antibodies for diagnosis.